CSBR - Champions Oncology Inc
(NaN%)
Sell
Gross Profit was Negative
26%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 761.51%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -4.18%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.18
Debt Ratio is 0.73
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is MODERATE
Cash from Operations Growth is 93.65%
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Champions Oncology Inc (CSBR) - https://championsoncology.com
Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms.Exchange - NASDAQ CAPITAL MARKET
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO -
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.